Non-Alcoholic Fatty Liver Disease Trial, Recruiting (NCT07294963)

Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT07294963 Sponsor: Khyber Medical University Peshawar Condition: Non-Alcoholic Fatty Liver Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07294963 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Non Alcoholic Fatty Liver Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People between 18 and 42 years of age.
People who have been diagnosed with fatty liver disease (also called NAFLD) using an imaging test such as an ultrasound.
People who have had their liver stiffness (fibrosis) measured and graded using a FibroScan test and a blood-based scoring method called the FIB-4 index.
People who are able to read and write, as the trial involves signing a consent form and completing written questionnaires and cognitive assessments.

Who may not be able to join:

People who drink more than 20 grams of alcohol per day (roughly 2 standard drinks).
People who have a long-term hepatitis B or hepatitis C infection.
People who have a significant mental health or psychiatric condition.
People who are currently pregnant or breastfeeding.
People who have certain long-term health conditions, including diabetes or a thyroid disorder.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dr Ayesha Qaiser, PhD Scholar, Khyber Medical University Peshawar

Phone: +92 332 9135697

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07294963

Sponsor: Khyber Medical University Peshawar

Phase: Not Applicable

Status: Recruiting

Condition: Non-Alcoholic Fatty Liver Disease

Trial contact: +92 332 9135697

More information: https://clinicaltrials.gov/study/NCT07294963

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People between 18 and 42 years of age.
People who have been diagnosed with fatty liver disease (also called NAFLD) using an imaging test such as an ultrasound.
People who have had their liver stiffness (fibrosis) measured and graded using a FibroScan test and a blood-based scoring method called the FIB-4 index.
People who are able to read and write, as the trial involves signing a consent form and completing written questionnaires and cognitive assessments.

Who may not be able to join:

People who drink more than 20 grams of alcohol per day (roughly 2 standard drinks).
People who have a long-term hepatitis B or hepatitis C infection.
People who have a significant mental health or psychiatric condition.
People who are currently pregnant or breastfeeding.
People who have certain long-term health conditions, including diabetes or a thyroid disorder.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Khyber Medical University Peshawar

Registry

ClinicalTrials.gov

Start date

1 October 2025

Est. completion

28 April 2026

Where this trial is recruiting

🇵🇰 Pakistan

Primary endpoints

Composite of Heart Failure Hospitalization or Cardiovascular Death; Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score; Change in N-terminal pro-brain natriuretic peptide (NT-proBNP); All-cause Mortality

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov